Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Opdivo plus Cabometyx approved in the EU for advanced renal cancer

pharmatimesApril 01, 2021

Tag: Opdivo , Cabometyx , Ipsen , BMS , advanced renal cell carcinoma

PharmaSources Customer Service